BCBS and CMS Tighten the Squeeze on Diagnostic Volume

Commercial payers and CMS are pressuring diagnostic economics, shifting value toward assays that can prove repeat-use utility and navigate tighter coverage rules.

Updated

What is this trend?

Payer rule changes and CMS fee cuts are tightening diagnostic volume, making reimbursement, prior authorization, and repeat-use evidence as important as assay performance.

  • BCBS plans are adding prior auth and medical-necessity review across broad lab menus.
  • CMS CLFS resets are cutting rates hardest in genomics, molecular pathology, microbiology, and immunology.
  • Serial-monitoring assays with guideline support are better positioned than one-off tests.
  • Coverage now depends on coding, workflow, and payer-specific rule design, not just FDA clearance.
  • Scale in billing and prior-auth operations is becoming a competitive advantage.

What’s the latest?

BCBS Illinois’ Sept.

Therapy-Specific Liquid Biopsy, Routed Telepathology, and Workflow-Control AI Tighten Diagnostic Control

How it developed

  1. Serial reimbursement, distributed biomarker workflows, and FDA-cleared claims are reshaping diagnostics commercialization
    • Reimbursement Is Shifting Diagnostics From One-Off Tests to Serial Monitoring

  2. Access gates tighten, workflow owners win, and pathology platforms scale across borders
    • EviCore Turns Guardant Shield Coverage Into a State-by-State Access Play

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Related trends

Stay ahead in Diagnostics & Informatics

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.